FCGR3A and COVID-19: Although plasma taken from individuals acutely infected with SARS-CoV-2 and vaccinated for COVID-19 is a helpful proxy in our in vitro CD16A reporter assays to assess Fc effector function, ideally, ADCC capacities should be assessed with primary NK cells collected from patients with SARS-CoV-2 across the severity spectrum.